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Aminoacyl tRNA synthetases (ARSs) link specific amino acids with their cognate transfer
RNAs in a critical early step of protein translation. Mutations in ARSs have emerged as
a cause of recessive, often complex neurological disease traits. Here we report an allelic
series consisting of seven novel and two previously reported biallelic variants in valyl-tRNA
synthetase (VARS) in ten patients with a developmental encephalopathy with microcephaly,
often associated with early-onset epilepsy. In silico, in vitro, and yeast complementation
assays demonstrate that the underlying pathomechanism of these mutations is most
likely a loss of protein function. Zebrafish modeling accurately recapitulated some of the
key neurological disease traits. These results provide both genetic and biological insights
into neurodevelopmental disease and pave the way for further in-depth research on ARS
related recessive disorders and precision therapies.
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Aminoacyl tRNA synthetases (ARSs) play a key role inprotein translation as they catalyze the attachment ofspecific amino acids to their cognate transfer RNA
(tRNA) molecules1,2. The nuclear encoded ARS gene loci are
subdivided into 17 cytoplasmic, 17 mitochondrial, and three bi-
functional ARSs3,4. The canonical aminoacylation and proof-
reading functions of ARSs are highly conserved across species. In
addition, during evolution many ARSs acquired additional
domains with unique structural characteristics that are not
essential for tRNA charging but account for non-canonical
functions5,6. These alternative functions are critical for cellular
homeostasis and include among others: regulation of signal
transduction and cell migration, angiogenesis and tumorigenesis,
inflammatory responses, and control of cell death5. This func-
tional diversity may in part account for the association between
mutations in ARS genes and a broad range of human disorders,
including neurological disorders, cancer, and auto-immune
diseases2.
Both monoallelic and biallelic pathogenic variants in ARS
genes, encoding dominant and recessive disease traits, respec-
tively, have been increasingly reported in patients with various
disorders that often have predominantly neurological features.
Dominant heterozygous mutations in ARS genes have been
identified in patients with Charcot-Marie-Tooth disease and
related peripheral neuropathies, including AARS7, GARS8,
HARS9,10, MARS11,12, WARS13, and YARS12,14. Recessive muta-
tions have been identified in complex disorders often involving
the central nervous system such as hypomyelination with brain-
stem and spinal cord involvement (DARS)15, leukodystrophy
(RARS)16, congenital visual impairment and progressive micro-
cephaly (KARS)17, developmental delay with progressive micro-
cephaly and intractable seizures (QARS)18,19 and early onset
epileptic encephalopathy with myelination defect (AARS)20.
Interestingly, some ARS genes have been associated with both
dominant and recessive disease traits including mutations in
AARS7,20, KARS21, and YARS14,22.
In this study, we report five newly diagnosed families with
biallelic variants in valyl-tRNA synthetase (VARS), including
seven novel VARS variants. In addition, we present an in-depth
description of two families previously reported in a large study on
brain malformations in mainly consanguineous families wherein
VARS was reported as a candidate disease gene23. In vitro studies
with patient-derived cell lines, including enzymatic assays, and
yeast complementation assays show that recessive VARS muta-
tions most likely lead to a loss-of-protein function, i.e. loss of
function (LoF) alleles. A vars knockout (KO) zebrafish model
further demonstrates that deficiency of vars results in micro-
cephaly and epileptiform activity, replicating key characteristics
of the human disease.
Results
Biallelic VARS variants cause developmental encephalopathy.
In total, ten patients from seven families with biallelic VARS
variants were identified (Fig. 1a)23. All families were included
through international collaborations or via the program Gene-
Matcher24. All patients had global developmental delay (DD),
which was already present in the first months of life in most
patients, and prior to seizure onset or unrelated to epilepsy in five
patients. All patients at a sufficient age for IQ testing had severe
or profound intellectual disability (ID) and were nonverbal. Only
two of the nine patients who had reached the walking age were
able to walk independently, though both acquired this skill only at
later age.
Eight out of ten patients had epileptic seizures, with onset
during the neonatal or infantile period in seven patients (mean: 6
mo, median 4.3 mo). Seizure types included generalized or
bilateral tonic-clonic seizures (seven patients), myoclonia (four
patients), tonic seizures (one patient), focal seizures (two
patients), and atypical absences (one patient). In patient 2,
migrating focal seizures were documented on EEG. In four
patients more than two anti-epileptic drug regimens failed
meeting the definition of drug resistance25. No seizures were
observed in patients 4 and 5 (family III), and repeated EEGs were
normal. Both siblings were reported to have a notably happy
demeanor resembling Angelman syndrome, but genetic testing
for this syndrome was negative.
Other clinical neurological features included (axial) hypotonia
(four patients), spasticity (five patients), and an ataxic gait (two
patients). Three patients were reported to have significant sleep
problems. Brain imaging showed cerebral atrophy in eight
patients and atrophy or partial agenesis of the corpus callosum
in four patients. Furthermore, hypomyelination or delayed
myelination was reported in four patients. All patients had a
severe, progressive microcephaly on the background of a more
general failure-to-thrive. Patients 9 and 10 (carrying the same
VARS variant) had additional systemic features including post-
natal anemia and hepatosplenomegaly in patient 9. Patient 10
died at the age of 3 years as a consequence of septic shock with no
history of immunodeficiency. A detailed summary of the clinical
findings in all patients is provided in Supplementary Data 1.
All patients were referred for genetic testing with WES or whole-
genome sequencing (WGS) after standard diagnostic work-up did
not reveal a cause for their neurodevelopmental disorder (details
available in Supplementary Notes 1 to 6). Three compound
heterozygous VARS variants were identified in the affected
members of families I (p.Leu434Val/p.Gly822Ser), II (p.Gln400Pro/
p.Arg442Gln), and III (p.Leu78Argfs*35/p.Arg942Gln). Of note, in
addition to the biallelic VARS variant, patient 3 also carried a rare de
novo variant of uncertain significance in the brain expressed gene
UBE2O which has been reported 1 time in the Exome Aggregation
Constortium (ExAC)26 (OMIM 617649, Supplementary Note 2).
Two homozygous missense variants identified in families IV
(p.Leu885Phe) and V (p.Arg1058Gln) were previously reported in
a large study on brain malformations in mainly consanguineous
families23 and in families VI (Jordan ancestry) and VII (Israel/Arabic
ancestry), the same, homozygous, p.Arg404Trp variant was identi-
fied. All VARS variants were deemed pathogenic based on their
absence or presence in very low frequency in ExAC and the Genome
Aggregation Database (gnomAD)26, impact on protein level, different
prediction tools, and segregation (Supplementary Table 1). All
identified variants were located in the catalytic or the anticodon-
binding domain of the protein with the exception of the frameshift
variant, which was not located in a specific domain (Fig. 1b).
In silico modeling in T. thermophilus ValRS. To gain insights
into the potential structural and functional consequences of the
human missense variants, the sequence of the human enzyme was
aligned to ValRS sequences from various taxa (Supplementary
Figure 1), including the T. Thermophilus ValRS sequence, whose
structure has been determined in complex with its cognate
tRNA27,28. Of the eight VARS missense variants identified, seven
could be mapped on to the corresponding residues in T. Ther-
mophilus ValRS, allowing inferences to be drawn regarding their
impact on protein structure and/or substrate interaction (Fig. 1c,
d and Supplementary Table 2). Employing this analysis, the
mutants fell into two different categories. The first category (6/7
variants) is composed of those substitutions that are likely to have
a direct or indirect effect on protein structure, owing to a loss of a
stabilizing interaction with one or more nearby residues. Sub-
stitutions falling into this category are p.Gln400Pro, p.Arg404Trp,
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Fig. 1 Identification of VARS variants in seven families with developmental encephalophaties and in silico predictions. a Pedigrees of the seven families
diagnosed with VARS mutations. b Location of the identified VARS variants on protein level (InterPro/P26640). c Ribbon cartoon model of the Thermus
thermophilus VARS-tRNA complex, highlighting the residues corresponding to those substituted in the human model. d Pair-wise comparisons between the
wild-type (left) and mutant (right) residues for predicted changes in local contacts with tRNA or other amino acids. Hydrogen bonds were indicated as
dotted yellow lines
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p.Leu434Val, p.Arg442Gln, p.Gly822Ser, and p.Arg1058Gln.
Prediction was weakest for p.Gln400Pro and p.Arg1058Gln as the
affected residues do not make particularly strong interactions
with other nearby residues. The second category (1/7) is defined
by the single mutant substitution (p.Arg942Gln), which alters a
direct contact to the transfer RNA substrate and, as such, could
interfere with tRNA binding. The remaining variant, p.Leu885-
Phe, is located in an insertion in helix α13 that is missing in T.
thermophilus ValRS and could not be modeled directly. Inspec-
tion of the structure of the complex suggests that this is located
potentially close to the N4 of the tRNA anticodon nucleotide C38
in the bound complex and may affect one or more direct contacts
to anticodon functional groups.
In vitro modeling in yeast and patient-derived cell lines.
Fibroblast lines of the two siblings of family III (patients 4 and 5)
with the compound heterozygous p.Leu78Argfs*35/p.Arg942Gln
variants were available for functional testing. Both cell lines
showed a statistically significant approximately twofold decrease
in VARS protein compared to a control line (Fig. 2a, p < 0.001,
one-way ANOVA). We hypothesized that this observation was
consistent with nonsense mediated mRNA decay (NMD) of the
mRNA bearing the frameshift allele and experimentally tested
this hypothesis by performing RT-qPCR before and after the
fibroblasts were treated with a translation inhibitor, cyclohex-
imide (CHX)29. In the patient fibroblasts there was a clear
absence of the frameshift allele at the cDNA level, which could be
reversed by CHX treatment (Fig. 2b). Immunofluorescence
staining further demonstrated that VARS is predominantly ER-
associated and that this localization was retained in patients 4 and
5 (Fig. 2c and Supplementary Figure 2). Extracts from these cell
lines were further assessed for their ability to support aminoa-
cylation. VARS activity from these mutated cell lines was sig-
nificantly reduced (<25%) relative to control fibroblasts, whereas
TARS activity was not, demonstrating that the observed reduction
in enzymatic activity was VARS specific (Fig. 2d).
To further assess the functional effects of pathogenicity of the
identified VARS missense variants, yeast complementation assays
were performed by modeling VARS variants in the S. cerevisiae
ortholog, VAS1. Complementation assays were performed for
all variants that were conserved between human and yeast
(p.Leu434Val, p.Arg442Gln, p.Gly822Ser, and p.Leu885Phe) on a
haploid yeast strain with the endogenous VAS1 gene deleted.
Viability of this strain was maintained via a URA3-bearing vector
(pRS316) with a wild-type copy of VAS1. Wild-type VAS1 on
pRS315 supported yeast growth while the empty pRS315 vector
did not (Fig. 2e) consistent with our experimental vector
harboring a functional VAS1 allele and with VAS1 being an
essential gene. The assays further showed that p.Leu434Val, p.
Arg442Gln, and p.Leu885Phe VAS1 alleles sustained yeast growth
to a level comparable to wild-type VAS1 (Fig. 2e). In contrast, p.
Gly822Ser did not support yeast cell growth at all (Fig. 2e)
consistent with p.Gly822Ser VARS being a functionally null allele.
These mutants were further tested for their ability to support
VARS enzymatic activity. Patient-derived lymphoblast lines
were available for patients 1 and 2 carrying the p.Leu434Val/p.
Gly822Ser variants, their heterozygous parents, and patient 9,
who was homozygous for the p.Arg404Trp variant. As shown
in Fig. 2f, VARS aminoacylation was decreased on the order of
50% in patients 1 and 2 relative to that of their parents (p < 0.05,
one-way ANOVA), whereas TARS aminoacylation was >100%
of the parental values. The p.Arg404Trp homozygote
(patient 9) variant showed an even greater loss of VARS activity,
on order of 25% relative to the heterogeneous parental samples
from family I.
Development of a vars knockout zebrafish model. The zebrafish
genome encodes a single VARS orthologue (67% identity and 77%
similarity at the amino acid level to human) with a highly con-
served catalytic domain (80% identity and 89% similarity). In
order to deduce the potential role of vars during development, its
expression patterns were examined during early development
(Fig. 3a). vars mRNA was found to be ubiquitously expressed at
18-somite stage at 18 hours post fertilization (hpf), with more
distinctive expression in the brain region and in the prospective
eye as well as in the hematopoietic intermediate cell mass and
somites, which was maintained till 24 hpf. From 36 hpf the
expression of vars became restricted to the developing brain, and
after 48 hpf it was also observed in other developing organs,
including branchial arches, liver, pancreas, and intestine (Fig. 3a
and Supplementary Figure 3). These dynamic expression patterns
strongly suggest an essential role of vars in the brain develop-
ment, while the expression outside CNS also suggests multiple
roles of vars during organogenesis.
To examine potential functional effects of VARS LoF in vivo,
we generated a vars knockout model using CRISPR/Cas9
technology in zebrafish30,31 (Supplementary Figure 4). Via RT-
qPCR, we confirmed that there was an almost complete lack of
total vars mRNA in vars−/− larvae at 3 and 5 days post
fertilization (dpf) and approximately half of the transcript present
in vars+/− larvae, proving the efficiency of the vars knockout
(Fig. 3b). Absence of vars in vars−/− larvae led to premature
death between 8 and 12 dpf (vars+/+ and vars+/− siblings
remained alive), suggesting an essential role for VARS in survival
(Fig. 3c). At 7 dpf about 35.3% of vars−/− larvae showed no
touch response, which was in marked contrast to the increasing
touch response demonstrated by vars+/+ and vars+/− over the
course of development (Fig. 3d). Loss of posture could be
observed in about 88.2% of vars−/− larvae already at 6 dpf
(Fig. 3d) and from 6 to 8 dpf ~50% of vars−/− larvae displayed
abnormal motor behavior such as jerky spasmodic movements
during touch response, in contrast to vars+/+ and vars+/− (data
not shown). Severe morphological abnormalities were observed in
vars−/− larvae from 3 dpf onwards, which were progressing over
the course of time. The most prominent features were micro-
cephaly with a partial loss of forebrain and snout, microphthal-
mia, and pericardial edema, as shown in bright-field images
(Fig. 3e and Supplementary Figure 5a). These dysmorphologies
were further investigated at the histological level on zebrafish
forebrain sections from 1 to 5 dpf (Fig. 3f). In 2 dpf vars−/−
larvae, aberrant cells desquamated into the ventricular space of
the forebrain and midbrain, which indicates substantial cellular
changes at an early stage of development (Supplementary Data 2)
that was not observed in the vars+/+ and vars+/− siblings.
Structural abnormalities progressed over time resulting at 5 dpf
in disrupted brain architecture, reduced jaw structures, delayed
retinal lamination, reduced lens, and periocular swelling around
the eye (corneal edema) (Fig. 3f and Supplementary Data 2).
Measurements taken from different head areas identified
significant reductions (p < 0.0001, one-way ANOVA) in head
and eye size at 3 dpf (Fig. 3g, i), that became even more
prominent at 5 dpf, where also the brain size was smaller
compared to vars+/+ and vars+/− siblings (Fig. 3g–i).
To determine whether the microcephaly was due to excessive
cell death in the brain, we assessed apoptosis by using antibody to
active caspase-3. There were significantly more apoptotic cells
detected in 3–5 dpf vars−/− brains (p < 0.001, one-way ANOVA)
than in those of their +/+ and +/− siblings (Supplementary
Figure 5b), whereas no statistically relevant difference was
observed at 2 dpf. Collectively, these results suggest that loss of
vars expression compromises zebrafish head and eye develop-
ment and that Vars is essential for neuronal survival.
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Fig. 2 In vitro studies support variant pathogenicity. a Western blot performed on patient-derived fibroblasts from patients 4 and 5 of family 3 carrying the
L78Rfs*35/R942Q VARS variant showed almost 50% reduction in VARS protein. Values are mean of three separate experiments. Error bars represent SD.
b RT-qPCR on the fibroblasts showed almost complete absence of the frameshift allele at mRNA level, treatment with cycloheximide caused a partial
increase in expression of the frameshift allele, which was not seen with DMSO-treated control. Values are mean of three separate experiments performed
in triplicate. Error bars represent SD. c Immunocytochemistry highlighted the nucleus (Hoechst), VARS and KDEL, a marker for endoplasmatic reticulum.
VARS co-localizes with KDEL. There was no difference in localization between the control line and the patient fibroblasts. d VARS and TARS
aminoacylation activity measured in extracts from the patient fibroblasts. The data were normalized to ATTC fibroblasts. VARS aminoacylation activity was
measured in technical triplicate at three separate passages, and TARS activity was measured once in technical triplicate. Data are represented as mean-
specific activity and error bars represent SEM. * indicates significant difference from control. e A haploid yeast strain deleted for endogenous VAS1 was
transformed with a LEU2-bearing pRS315 vector containing wild-type VAS1, the indicated mutant form of VAS1, or no insert (empty). Cultures for each
strain (labeled along the top) were either undiluted (UD) or diluted 1:10 or 1:100 and then spotted on solid medium containing 5-FOA to determine whether
the VAS1 alleles complement loss of endogenous VAS1 at 30 °C. Only G822S shows absent growth indicating a functional null allele. f VARS and TARS
aminoacylation activity measured in extracts from patient-derived lymphoblasts of patients 1 and 2 (L434V/G822S) and their parents and patient
9 (R404W). Data were normalized to the paternal cells. VARS aminoacylation activity was measured in technical triplicate at three separate passages,
and TARS activity was measured once in technical triplicate. Data are represented as mean-specific activity and error bars represent SEM. * indicates
significant difference from L434V paternal lymphoid cells. In a, b, d, and f one-way ANOVA with Tukey’s multiple comparisons test was used. Significant
values are noted **p < 0.01, ***p < 0.001, and ****p < 0.0001
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Behavioral and electrophysiological studies in zebrafish.
Changes in behavioral activity were investigated by performing
tracking experiments. vars−/− larvae showed significantly
decreased swimming activity from 4 till 7 dpf (p < 0.0001, one-
way ANOVA) in comparison to vars+/+ and vars+/− (Fig. 4a).
In addition, we examined if vars−/− larvae possessed learning
deficits by performing a habituation assay32. In the experiment, 6
dpf larvae were subjected to multiple dark flashes (DFs) alter-
nated with light periods. Similarly to vars+/+ and vars+/−,
vars−/− larvae could adapt to DFs during a training period as
shown by their movement values decreasing over time (Fig. 4b).
Interestingly however, the motion of vars knockout larvae in
response to DF was significantly increased (p < 0.0001, one-way
ANOVA).
To investigate whether vars knockout resulted in abnormal
brain activity electrographically, we recorded local field potentials
(LFPs) on larval optic tecta of 5, 6, and 7 dpf vars−/−, vars+/−,
and vars+/+ zebrafish larvae. Epileptiform events were defined as
multi-spike bursts with amplitudes equal to or exceeding
threefold the baseline (Fig. 4c). Recurrent spontaneous
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epileptiform events occurred in vars−/− at all days, being most
prominent at 5 dpf where 68.57% of the larvae displayed
abnormal activity, whereas no vars+/− and only 5.26% of
vars+/+ showed similar events (Fig. 4d). At 6 and 7 dpf, in 47.62
and 52.63% of vars−/− larvae, respectively, electrographic seizure
activity could be detected.
The morphological and behavioral phenotype of our vars−/−
CRISPR model was fully recapitulated and confirmed in the
varsHi558Tg−/− zebrafish line, bearing a retroviral insertion in the
first intron of vars (Supplementary Figure 6).
Rescue experiments with human VARS mRNA. To further
validate the specificity of the vars knockout phenotype traits with
respect to modeling neurological disease and to determine the
functional consequence of selected variants identified in patients,
we performed rescue experiments through mRNA injections of
either wild type or mutated human VARS into vars−/− CRISPR
embryos. Supplying WT VARS led to a partial or full rescue of the
early phenotype in vars−/− larvae. In early development (3 dpf), a
statistically significant increase for the head, brain, and eye size
was observed (p < 0.001, one-way ANOVA, Fig. 5a–c, respec-
tively). A significantly ameliorated touch response (p < 0.001, one-
way ANOVA, Fig. 5d), occurred in tandem with the improvement
of locomotor activity being most prominent at 5 dpf (Fig. 5e),
suggesting a late response. These results were supported by the
presence of exogenously supplied human WT VARS mRNA
detected in vars−/− larvae at 1, 3, and 5 dpf (Fig. 5f).
In order to provide further evidence for the disease-causing
nature of some of the variants, human VARS mRNA with mutant
substitutions in the catalytic (p.Gln400Pro) and anticodon binding
domains (p.Arg942Gln and p.Arg1058Gln) were tested for their
ability to complement the vars knockout phenotype. For this
experiment, we employed the early phenotype readout at 3 dpf. In
contrast to the results with WT human VARS mRNA, none of the
injections of human mutated VARS mRNA rescued head size or
brain size of vars−/− larvae (Fig. 5g, h, respectively). Among the
three variants, only the p.Arg942Gln variant provided a partial
rescue of the eye size phenotype (Fig. 5i). These observations
confirmed that, despite differences in their predicted impact on
VARS structure and mechanism, all three variants displayed a loss
of function when tested in our vars zebrafish model.
Discussion
Aminoacyl-tRNA synthetases have an indispensable function in
protein translation, which explains their extensive conservation
throughout evolution and the fact that mutations in this class of
proteins have been increasingly associated with human disease.
To date, a total of 31 out of 37 ARS enzymes have been implicated
in genetic diseases, which often include neurological features2.
We studied ten patients with biallelic VARS variants and report
seven new variants. Detailed clinical evaluation revealed devel-
opmental delay, early onset epilepsy, and microcephaly as key
clinical characteristics. While no specific epilepsy syndrome could
be associated with VARS mutations, a single patient (patient 2)
had an EEG confirmed diagnosis of epilepsy of infancy with
migrating focal seizures (EIMFS). Notably, this clinical diagnosis
was also found in a patient with a recessive QARS mutation18,
suggesting a potential link between this rare type of epilepsy and
dysfunction of aminoacyl-tRNA synthetases. Two patients
(patients 4 and 5) never manifested seizures. Interestingly, these
two patients had a normal brain MRI, whereas cerebral atrophy,
hypoplasia or atrophy of the corpus callosum and hypomyeli-
nation or delayed myelination were recurrent findings in the
other patients. Both siblings also had severe intellectual disability
to the same degree as most other VARS patients. Clinical features
closely resembling the phenotype to the patients with VARS
mutations described in this study have been observed for muta-
tions in other members of the cytoplasmic ARS family, most
striking in patients with biallelic mutations in QARS18,19, KARS17,
and AARS20,33. This may indicate a joint phenotypic spectrum
associated with certain aminoacyl-tRNA synthetases defects that
predominantly involves developmental delay, epilepsy, and
microcephaly. Interestingly, also the phenotype associated with
biallelic mitochondrial VARS2 variants showed some similar
features34. This illustrates the importance of including a broad set
of genes involved in protein translation in the screening of
patients with developmental (and epileptic) encephalopathies.
Eight of the nine identified VARS variants were missense
variants located in or near the catalytic or tRNA binding
domains. The p.Leu78Argfs*35 variant, occurring in the com-
pound heterozygous state with the p.Arg942Gln missense variant,
was the only truncating VARS variant reported in our series. The
frameshift allele was shown to be prone to NMD resulting in a
clear decrease in expression of the mutated mRNA and protein,
and decrease in VARS aminoacylation activity, consistent with a
LoF allele. Immunofluorescence staining further showed that
VARS is predominantly localized at the ER. This expression
pattern was not altered in fibroblasts in the presence of the
p.Leu78Argfs*35/p.Arg942Gln variants.
To gain further insight into the pathogenic nature of the
missense variants we performed predictive in silico studies of all
mutations. Next, we supplemented this preliminary mutational
analysis with biochemical, developmental, and neurological trait
studies of selected pathogenic variant alleles in yeast, patient-
derived cell lines and/or zebrafish. While a full functional char-
acterization of each missense mutant was not performed, com-
bined predictive and focused biochemical studies of different
Fig. 3 vars−/− larvae display severe developmental phenotype with early lethality. a Spatiotemporal expression patterns of vars by whole-mount RNA
in situ hybridization at 18, 24, 36, and 72 hpf. BA Branchial Arches; H Hindbrain; HICM Hematopoietic Intermediate Cell Mass; Ints Intestine; Liv Liver;
MBH Midbrain-Hindbrain boundary; M Midbrain; R Retina. Scale bars= 200 μm b RT-qPCR data demonstrating the expression of total vars in vars+/+,
vars+/−, and vars−/− larvae at 3 and 5 dpf. Values are mean of three separate experiments performed in triplicate. c Kaplan–Meier survival curve of
vars+/+ (n= 37), vars+/− (n= 82), and vars−/− (n= 34) larvae. d Graph illustrating changes in loss-of-posture and touch response of vars−/− larvae
throughout the life span. Only the surviving larvae were included. e Representative lateral and dorsal bright-field images of 3 and 5 dpf vars+/+, vars+/−,
and vars−/− larvae (scale bar, 500 μm). Pericardial edema, small eye, and periocular swelling around the eye were marked with arrows. f H&E histological
staining of paraffin-embedded coronary sections from the forebrain of 1–5 dpf vars+/+, vars+/−, and vars−/− larvae (scale bar, 100 μm). Magnification of
the disruption in the organization of the brain and the eye for 5 dpf vars+/+, vars+/−, and vars−/− was marked with black and green stripped line,
respectively. Red arrows point out some structural abnormalities. D diencephalon; IPL inner plexiform layer; L lens; MC mandibular cartilage; ON optic
nerve; OPL outer plexiform layer; R&C rods and cones; RGC retinal ganglion cell; T trabecula. g–i Comparison of the individual measurements for head size
g, brain size h, and eye size i for vars+/+, vars+/−, and vars−/− at 3 dpf (n= 9, n= 20 and n= 11, respectively) and 5 dpf (n= 9, n= 14 and n= 24,
respectively). In b and g–i one-way ANOVA with Tukey’s multiple comparisons test was used. Values are mean of three separate experiments. In c log-
rank (Mantel-Cox) test was used. Error bars represent SD. Significant values are noted as ***p < 0.001 and ****p < 0.0001
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variants gave us sufficient information to make a statement about
the pathogenic nature of most variants. Substitutions p.Gly822-
Ser, p.Leu434Val, p.Arg442Gln and p.Arg404Trp were each
characterized by a potential destabilization of structure. While
stability was not investigated directly, the results of yeast com-
plementation analysis indicated that p.Gly822Ser clearly failed
to complement, while p.Leu434Val and p.Arg442Gln were still
positive for complementation. Aminoacylation assays on patient-
derived cell lines further showed a clear decrease in function
for p.Leu434Val, p.Gly822Ser and p.Arg404Trp. On the
other hand, substitutions p.Arg942Gln and p.Leu885Phe were
predicted to cause impaired recognition of substrates. The pre-
dicted tRNA binding mutant p.Arg942Gln exhibited only weak
rescue of VARS function in the zebrafish knockout, and also
contributed to the decreased aminoacylation seen in cell lines
derived from the siblings carrying the variant. As such, this
variant likely represents a hypomorphic VARS allele. The p.
Leu885Phe variant was positive for yeast complementation, but
was not tested for its ability to rescue the vars−/− zebrafish.
Modeling analysis for the two missense variants p.Gln400Pro,
and p.Arg1058Gln predicted a slightly lower likelihood of a
potential protein destabilization. Nevertheless, neither p.
Gln400Pro nor p.Arg1058Gln were able to rescue the zebrafish
vars knockout providing experimental evidence for variant allele
pathogenicity. This observation highlights the value of the zeb-
rafish in vivo model to differentiate between pathogenic and
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Fig. 4 vars−/− larvae show cognitive deficits and spontaneous seizure like behavior. a Behavioral activity (average total movement) of vars+/+ (n= 58),
vars+/− (n= 108), and vars−/− (n= 58) larvae from 4 to 7 dpf expressed in actinteg units. Values are mean of three separate experiments. b Habituation
assay performed on 6 dpf vars+/+ (n= 19), vars+/− (n= 47), and vars−/− (n= 30) larvae was composed of four blocks with 120 DFs with 15 s ISI
(regions with black and yellow stripes), alternated by 10min of light (yellow areas). The linear slopes between the actinteg responses were calculated
(dotted lines) and compared between the different genotype groups (green circles—vars+/+, black circles—vars+/−, and red circles—vars−/−). DF dark
flashes, ISI interstimulus intervals. Values are mean of two separate experiments. c Representative recording from optic tectum of 6 dpf vars−/− larva
displaying polyspike discharges. Top trace represents typical pattern of epileptiform activity. Bottom trace shows magnification of the epileptiform event.
d Percentage of larvae exhibiting spontaneous electrographic activity recorded from 5 dpf vars+/+ (n= 19), vars+/− (n= 31), and vars−/− (n= 35),
6 dpf vars+/+ (n= 20), vars+/− (n= 30) and vars−/− (n= 48) and 7 dpf vars+/+ (n= 12), vars+/− (n= 13) and vars−/− (n= 19) larvae. Abnormal
brain activity was observed in 68.57% (24/35) 5 dpf vars−/−, 5.26% (1/19) 5 dpf vars+/+, 47.62% (23/48) 6 dpf vars−/−, 5% (1/20) 6 dpf vars+/+,
6.67% (2/30) vars+/−, 52.63% (10/19) 7 dpf vars−/− and 8.33% (1/12) 7 dpf vars+/+. In a and b one-way ANOVA with Tukey’s multiple
comparisons test was used. In d—Fisher’s exact test was used. Significant values are noted *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Error
bars represent SD
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Fig. 5 Wild-type human VARS mRNA partially rescues early zebrafish phenotype, whereas mutated constructs do not. a–c Comparison of the individual
measurements for head size a, brain size b, and eye size c for WT human VARS-injected vars−/− larvae (n= 12). GFP-injected vars+/+ larvae (n= 9)
were used as a positive control, whereas GFP-injected vars−/− larvae (n= 24) served as a negative control. Values are mean of three separate
experiments. d Curves illustrating the evolution of touch response during the life span of vars−/− larvae injected with WT human VARS (n= 12) and GFP
mRNA (n= 11) (negative control). vars−/− GFP-injected larvae were used as a positive control. e Average total movement of WT human VARS-injected
(n= 10) and GFP-injected (n= 9) vars−/− larvae from 3 to 7 dpf. vars+/+ GFP-injected larvae (n= 14) were used as a control. f RT-qPCR data
demonstrating expression levels of injected human WT VARS in vars−/− larvae at 1, 3, and 5 dpf. At 3 and 5 dpf there was 24.55% and 10.42%WT VARS
mRNA left, respectively, in comparison to 1 dpf. Values are mean of three separate experiments performed in triplicate. g–i Comparison of the individual
measurements for head size g, brain size h, and eye size i for human mutated Q400P (n= 15), R942Q (n= 18) and R1058Q (n= 7) VARS-injected vars
−/− larvae. GFP-injected WT larvae (n= 9) were used as a positive control, whereas GFP-injected vars−/− larvae (n= 24) served as a negative control.
Values are mean of three separate experiments. In a–c and g–i one-way ANOVA with Tukey’s multiple comparisons test was used; in d—log-rank (Mantel-
Cox) test; in e—unpaired t-test. Significant values are noted *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Error bars represent SD
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potentially benign VARS variants with respect to the human
neurological disease traits studied.
Based on the above observations, we hypothesize that biallelic
disease-causing VARS variants consist of a combination of a loss-
of-function allele and a hypomorphic allele or alternatively a
combination of two hypomorphic alleles that decrease overall
VARS levels below a threshold where protein synthesis and/or
other VARS-specific functions are critically threatened. Homo-
zygosity or compound heterozygosity for null alleles would be
lethal due to the essential function of VARS in all cells. Impor-
tantly, this hypothesis is supported by our observation that cer-
tain disease-associated VARS alleles retain some function. For
example, p.Leu434Val VARS, when modeled in yeast, allowed
cellular growth, which is expected as this mutation is opposite the
functional null allele p.Gly822Ser VARS. Similarly, p.Leu885Phe
VARS allowed yeast cell growth, which is expected since this allele
was identified in the homozygous state. It is important to point
out that our yeast assay may not be able to detect more subtle
defects in enzyme function as we have shown for KARS and
AARS mutations associated with recessive disease20,21.
While we acknowledge the vars knockout zebrafish model is
not a perfect genetic model for the human disease, we showed it
accurately recapitulated many of the phenotypic features. In
particular, microcephaly and epileptic activity, as seen in the
patients, could also be observed in the zebrafish. Moreover,
hyperactivity in vars−/− larvae observed upon light switches
suggests a neuromodulatory effect, as the behavior depends on
sensory input and is regulated by neuronal connectivity of the
hindbrain and spinal cord and multiple neurotransmitter path-
ways35. We showed that vars was strongly and selectively
expressed in the developing brain, eye and other organs during
embryogenesis, as such, it is not surprising that loss of vars
expression severely compromised zebrafish development. Inter-
estingly, a qars knockout and iars knockdown zebrafish model
showed some features similar to the vars model including brain
malformations and extensive cell death in the brain18,36. How-
ever, the behavioral and epileptic phenotype of the qars and iars
model were not further investigated and therefore cannot be
compared to our model. Noteworthy, microcephaly and micro-
phthalmia seems to be a more general phenotype associated with
ARS mutations in zebrafish, since several mutant ARS lines (kars,
mars, sars, and qars), identified in a large insertional mutagenesis
screen, displayed it37.
Our results suggest that the pathomechanism of biallelic VARS
variants, and possibly of recessive ARS disease more general, is a
loss-of-protein function. This contrasts with dominant mutations
in ARS genes which are nearly uniformly associated with
Charcot-Marie-Tooth disease, or less common peripheral neu-
ropathies, and their functional effects likely differ (hypothesized
dominant negative or gain-of-function effect)2. This interpreta-
tion is further supported by the fact that parents of patients with
recessive VARS-associated phenotypes, who carry the mutation
in a heterozygous state, are consistently reported to be phenoty-
pically normal. Indeed, a 50% reduction in VARS activity can be
tolerated without significant pathology, which is also supported
by the presence of heterozygous truncating variants in public
databases like ExAC and gnomAD26.
Noteworthy, pathogenic variants in other genes that encode
proteins with a prominent role in translation, can cause similar
neurological disease traits to the ones associated with pathogenic
variants in ARSs. For instance, CLP1, which encodes an RNA
kinase responsible for tRNA splicing required for tRNA
maturation, causes microcephaly in humans, mice and zebrafish
and peripheral neuropathy in humans38,39.
Further studies on VARS, both in vitro and in the zebrafish
model, may focus on gaining more functional insight into the
underlying pathomechanism for the neurological disease traits
focusing on the disrupted translational machinery and altered
proteostasis or other non-canonical functions, and their effect on
brain, nervous system, and global development. The zebrafish
model further provides an excellent system for testing multilocus
variation genetic models40 and future compound screenings in
the search for precision medicine directed therapies for these
severe disorders.
Methods
Ethics. All human research complied with all relevant ethical regulations and was
approved by the relevant institutional review boards and the Ethical Committee of
the University of Antwerp. Informed consents were obtained from all patients or
their legal guardians in the respective centers where patients were recruited. Zeb-
rafish experiments complied with all relevant ethical regulations and were
approved by the Ethics Committee of the University of Leuven (Ethische Com-
missie van de KU Leuven, approval number ECD P150/2015) and by the Belgian
Federal Department of Public Health, Food Safety and Environment (Federale
Overheidsdienst Volksgezondheid, Veiligheid van de Voedselketen en Leefmileu,
approval number LA1210199).
Genetic and phenotypic analysis. Molecular genetic analyses were performed in
different research and diagnostic centers for which the details are given in Sup-
plementary Notes. Families 3 and 6 were ascertained through the program Gen-
eMatcher24. The seven novel VARS variants were all identified with WES or WGS
in patients for whom standard diagnostic work-up failed to identify the cause of
their neurodevelopmental phenotype. Variant filtering was done through locally
developed pipelines taking into account the quality of the variant calling, presence
in population databases, predicted impact on the encoded protein and segregation
of the variants. VARS transcript NM_006295.2 was used for variant nomenclature.
Clinical information was collected using standardized clinical templates that were
completed by collaborating clinicians and geneticists. International League Against
Epilepsy (ILAE) criteria were used for epilepsy syndrome classification when
applicable41.
In silico modeling of VARS variants. The protein coding sequences of valyl-tRNA
synthetases (VARS) were extracted from the UniProt server. The organisms and
the UniProt accession numbers for their VARS sequences are as follows: Escher-
ichia coli (E. coli), P07118; Thermis thermophilus (Thermis), P96142; Sacchar-
omyces cerevisiae (yeast), P2637; Drosophila melanogaster (fruit fly), Q0E993;
Caenorhabditis elegans (worm), Q23360; Danio rerio (zebrafish), F1Q740; Mus
musculus (house mouse), Q9Z1Q9; Homo sapiens (human), P26640. Multispecies
alignments were generated by use of Clustal Omega42. The alignment was further
annotated in the protein ENDscript43 with secondary structures derived from the
structure of the ValRS-tRNAVal from Thermis thermophilus (PDB ID: 1IVS) as
reported earlier27,28. The alignments were used to identify residues in the Thermis
thermophilus complex corresponding to the residues altered by the VARS muta-
tions, and then the resulting structures were rendered in space filling or stick
representation using the program PyMOL (The PyMOL Molecular Graphics Sys-
tem, Version 1.2r3pre, Schrödinger, LLC).
Isolation of patient-derived cell lines and cell culture. Skin biopsies of patients 4
and 5 of family 3 (p.Leu78Argfs*35/p.Arg942Gln) and of a control individual were
obtained following the local standard protocol and fibroblasts lines were generated.
Fibroblasts, continuously kept at 37 °C in a humidified atmosphere with 5% CO2,
were cultivated in Dulbecco’s Modified Eagle Medium (DMEM), high glucose
(Gibco) enriched with 10% heat-inactivated fetal bovine serum (Gibco), 1% L-
glutamine (Life Technologies), 1% penicillin-streptomycin (Life Technologies).
Lymphoblast lines were generated from fresh (peripheral) blood samples for
patient 1, 2 and their parents (p.Leu434Val/p.Gly822Ser); and patient 9 (p.
Arg404Trp) according to local standard protocol. The cells, continuously kept at
37 °C in a humidified atmosphere with 6% CO2, were cultivated in RPMI 1640
Medium (Gibco), enriched with 10% heat-inactivated fetal bovine serum (Gibco),
1% L-glutamine, 1% penicillin-streptomycin and 1% sodium pyruvate (Life
Technologies).
Western blot. Pelleted fibroblasts of patients 4, 5, and a control individual were
homogenized in lysis buffer (20 mM Tris-HCl, pH 7.4, 2.5 mM MgCl2, 100 mM
KCl, 0.5% NP-40) supplemented with protease inhibitors (Sigma), placed on ice for
30 min and cleared by centrifugation for 10 min at 20,800×g. Protein concentra-
tions were determined using a Pierce BCA Protein Assay Kit (Thermo Fisher
Scientific). Equal amounts of protein were diluted in NuPage LDS sample buffer 4X
(Thermo Fisher Scientific) supplemented with 100 mM 1,4-dithiothreitol (DTT).
Samples were denatured for 5 min at 95 °C. Subsequent size separation was per-
formed with SDS-polyacrylamide gel electrophoresis on NuPAGE Novex 4–12%
Bis-Tris gels (Thermo Fisher Scientific), which was later electrotransferred to a
nitrocellulose membrane (GE Healthcare Lifescience). Membranes were blocked in
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5% milk powder diluted in PBS-Tween 20 (0.1%) for 1 h. Primary antibody was
incubated overnight at 4 °C or for 1 h at room temperature (RT) followed by
secondary antibody for 1 h at RT. Visualization was effected with enhanced che-
miluminescence detection using Amersham ECL Prime Western Blotting Detec-
tion Reagent (GE HealthCare) and an ImageQuantTM LAS4000 system (GE
Healthcare Life Sciences). The density of the resulting bands, corrected for loading,
was quantified using ImageJ and statistical significance assessed by one-way
ANOVA with Bonferroni’s multiple comparisons test. The following primary
antibodies were used: anti-VARS antibody (1:2500, Atlas Antibodies, HPA046710)
and anti-alpha-tubulin (1:5000, Abcam, ab4074). The following secondary anti-
bodies were used: anti-rabbit HRP-conjugated (1:10,000, Promega, W401B), anti-
mouse HRP-conjugated (1:10,000, Southern Biotech, 1070–05). Uncropped scans
of blots are available in Supplementary Figure 7.
qPCR of cycloheximide-treated cells. Confluent T75 flasks of fibroblasts of
patients 4, 5 and a control individual were treated for 6 h with (i) cycloheximide
(CHX) (150 µg/mL), with (ii) dimethyl sulphoxide (DMSO) as a negative solvent
control, or (iii) without treatment. After 6 h cells were collected, pelleted, and
subsequently subjected to RNA extraction (Qiagen RNeasy Mini Kit), and followed
by DNase treatment to remove residual genomic DNA (Turbo DNA free, Ambion).
One microgram of total RNA was converted to cDNA using the Superscript® III
First Strand Synthesis System (Life Technologies) with both oligo dT and random
hexamer primers.
Primers for real-time detection of VARS were custom-made (Supplementary
Table 3) and a reaction mixture containing 20 ng cDNA template, primers and
Power SYBR Green PCR Mastermix (Life Technologies) was amplified under
cycling conditions according to the manufacturer’s protocol. Data were generated
on a ViiATM7 Real-Time PCR system (Life Technologies) and analysed using
Qbase+ (Biogazelle)44. VARS transcripts were normalized against 4 housekeeping
genes (GAPDH, HPRT1, SDHA, and HMBS). The ΔΔCq method was used to
determine the relative levels of mRNA expression between experimental samples
and controls. The results consist of data from at least two separate experiments
where samples were run in triplicate. One-way ANOVA with Tukey’s multiple
comparisons test was used to determine statistical significance.
Immunocytochemistry. For immunofluorescence (IF) staining of intracellular
VARS protein, 50,000 fibroblasts of patients 4, 5 and a control individual were
seeded on 12 mm diameter coverslips and 24 h later fixed with 4% paraf-
ormaldehyde (PFA) for 20 min at RT. Fibroblasts were permeabilized with 0.5%
Triton X-100 in phosphate-buffered saline (PBS) for 2 min, blocked with 0.5%
bovine serum albumin and 0.2% goat serum for 1 h and incubated overnight at 4 °C
with following primary antibodies: anti-VARS protein (1:500; Atlas Antibodies,
HPA046710), anti-KDEL (1:100; Enzo Life Sciences, 10C3), anti-Golgin-97 (1:200,
Life Technologies, A21270), and anti-TOMM20 (1:200, Abcam, ab56783). With
intermediate PBS washing steps, the secondary antibodies goat anti-rabbit IgG
(Alexa Fluor 488) and goat anti-mouse IgG (Alexa Fluor 594) (both 1:500; Life
Technologies) were added for 1 h at RT. Nuclei were stained for 10 min with
Hoechst 33342 (1:10,000, Life Technologies). Coverslips were mounted (Dako) and
images were taken with a Zeiss LSM700 confocal microscope using a ×63/1.40
plan-apochromatic objective. Possible cross-talk of the fluorescence channels was
excluded by using frame-by-frame scanning.
Aminoacylation assay. Protein extracts containing aminoacyl-tRNA synthetase
activity were prepared from ATTC control cells or patient-derived cell lines as
described above. After washing twice with cold Dulbecco’s PBS, cells were lysed in
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM DTT, 0.5% Triton X-100, and
protease inhibitor cocktail (Sigma). Protein concentration was measured by the
standard Bradford assay. Aminoacylation assays were performed at 37 °C in 100
mM HEPES, pH 7.2, 30 mM KCl, 10 mM MgCl2 with 107 μM total human pla-
cental tRNA, 2 mM ATP, 50 μM [14C] valine (282.8 mCi/mmol), and were initiated
by the addition of protein extract to a final concentration of 0.3 μg/µL of total
protein. At three different time points over a 10-min interval, 5 µL aliquots were
spotted onto 3MM Whatman filter papers presoaked with 5% TCA. The dried
filters were washed three times with 5% TCA, once with 95% ethanol, then the
radioactivity was quantitated by liquid scintillation. To calculate the specific activity
of each sample, aminoacylation rates (pmol aminoacylated tRNA/min) were cal-
culated from linear fits of the progress curve data, corrected for the total protein
concentration.
Yeast complementation assay. VAS1 expression constructs for yeast com-
plementation assays were generated using Gateway Cloning Technology (Invitro-
gen). The VAS1 gene (including the endogenous promoter sequence) was amplified
from purified S. cerevisiae genomic DNA with primers bearing Gateway sequences.
The resulting PCR product was BP-cloned into the pDONR221 entry vector per
the manufacturer’s instructions. The BP reaction was used to transform E. coli,
colonies were purified and subjected to Sanger sequencing to confirm sequence
specificity and the absence of PCR-induced errors. Mutations assayed were gen-
erated using the QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene)
and variant-specific mutagenic primers (Supplementary Table 3). Mutagenesis
reactions were performed on VAS1 pDONR221 constructs, which were subse-
quently transformed into E. coli. DNA from individual clones was purified and
subjected to Sanger sequencing to confirm the presence of each mutation and to
rule out PCR-induced errors. Two sequence-validated constructs each for wild-type
VAS1 or the indicated mutations modeled in VAS1 (Fig. 2d) were LR-cloned into
pRS315 according to the manufacturer’s instructions. LR reactions were then used
to transform E. coli, and colonies were purified and digested with BsrG1 (New
England Biolabs) to confirm the presence of the respective VAS1 insert.
Yeast complementation assays were carried out using a haploid S. cerevisiae strain
with a deletion of the endogenous VAS1 locus. Viability of this strain was maintained
via a pRS316 vector (including a URA3 gene) bearing a wild-type copy of VAS145. The
haploid ΔVAS1 strain was transformed with wild-type VAS1, mutant VAS1, or empty
pRS315 bearing no VAS1 insert; pRS315 includes a LEU2 gene. Transformed yeast
cells were selected for the presence of both vectors by growth on media lacking uracil
and leucine. Two yeast colonies per transformation were selected for analysis and
grown to saturation in 2mL CM glucose broth (minus leucine and minus uracil) for
48 h at 30 °C. Cultures were either undiluted or diluted 1:10 or 1:100 in water.
Subsequently, 10 μL of undiluted and diluted cultures were spotted on complete solid
media containing 0.1% 5-fluoroorotic acid (5-FOA; Teknova) to select for
spontaneous loss of the maintenance vector. Yeast viability was visually assessed after
3 days of incubation at 30 °C. Two colonies per transformation were assayed and each
transformation was repeated three times using two independently generated
constructs of either wild-type or the respective mutant VAS1.
Zebrafish husbandry. All zebrafish (Danio rerio) lines used in this study were
maintained at 28.5 °C on a 14 h light/10 h dark cycle under standard aquaculture
conditions in a UV-sterilized rack recirculating system equipped with a mechanical
and biological filtration unit. Fertilized eggs were collected via natural spawning
and were raised in Danieau’s medium (1.5 mM HEPES, pH 7.2, 17.4 mM NaCl,
0.21 mM KCl, 0.12 mMMgSO4, 0.18 mM Ca(NO3)2 and 0.6 μMmethylene blue) in
an incubator on a 14 h light/10 h dark cycle at 28.5 °C.
Whole-mount RNA in situ hybridization (WISH). One kb coding sequence
fragment of vars was amplified from cDNA of AB wild-type strain (primers in
Supplementary Table 3) and cloned into Zero Blunt® TOPO® PCR Cloning Kit
(Invitrogen). Cloned DNA was linearized by XhoI and HindIII, then synthesized
by SP6 RNA polymerase and T7 RNA polymerase using DIG RNA labeling kit
(all Roche) for sense- and anti-sense DIG-labeled RNA probes, respectively.
Embryos were fixed with 4% PFA, then washed with 1X PBS with Tween 20
(PBST), sequentially washed with 100–25% methanol and stored in 100% methanol
at −20 °C until needed. On the first day of WISH, embryos were washed with
50–25% methanol, followed by 1X PBST. After treatment with proteinase K
(Sigma) according to the developing stages, for permeabilization embryos were
fixed again with 4% PFA and washed by 1X PBST. Embryos were hybridized in
Hyb+ solution with the vars RNA probes at 70 °C overnight. On the second day,
after serial washing with 2X SSCTw/50% formamide, 2X SSCT, 0.2X SSCT at 70 °C,
embryos were blocked with 5% horse serum (Sigma) and incubated with anti-
digoxigenin-AP Fab fragments (Roche) overnight at 4 °C. On the third day,
embryos were developed with BCIP/NTP substrate (Roche). Staining was
developed and stopped before the background signals started to appear in the
embryos hybridized with the sense RNA probe.
Generation of the vars CRISPR knockout zebrafish line. A KO vars fish line was
generated via CRISPR/ Cas9 technique30,31. vars sgRNA targeting exon 21 in the
catalytic domain of vars protein (5′-CCGTCTCTAACAGTGTGCCC(GGG)-3′)
was designed via GeneArt (Invitrogen) and further transcribed using MEGA-
shortscript™ T7 Transcription Kit (Ambion) and purified with MEGAclear™
Transcription Clean-Up Kit (Ambion). Cas9 (GeneArt CRISPR Nuclease mRNA)
was purchased from Invitrogen. Single cell-stage fertilized wild-type embryos of AB
line were injected with 7 pg vars sgRNA and 150 pg Cas9 mRNA (1 nL volume).
The mutation at the target site was verified via Sanger sequencing. The remaining
sgRNA/Cas9-injected embryos were raised till adulthood and outcrossed with WT
adults. DNA extracted from F1 generation of 3 dpf whole larvae was screened for
indels by Sanger sequencing. F0 founder with germline transmission and high rate
of indels was selected to establish the knockout line. F1 generation embryos were
raised to adulthood, fin clipped and sequenced. Individuals carrying the same
mutation (4 bp deletion of GGGC) were identified and pooled together. All
experiments were performed on embryos coming from F2 or F3 progeny.
To confirm the genotype of the larvae, prior to or at the conclusion of an
experiment, a whole larva or fin clip, respectively, was placed in separate tubes with
50 μL of lysis buffer (100 μM Tris, 10 μM EDTA, 0.7 mM proteinase K and 0.2%
Triton X-100) to extract genomic DNA. Lysis was performed at 55 °C for 3 h,
followed by 10 min at 95 °C. Lysed samples were genotyped by performing a PCR
to amplify a 466 bp-region of interest (containing vars 4 bp deletion) using
Titanium® Taq DNA Polymerase (Takara) and vars-specific primers
(Supplementary Table 3). Successfully amplified PCR products were purified using
ExoProStar (Illustra™) and Sanger sequenced with the same primers used for
amplification. The genotypes of the individual larvae were analysed using SeqMan
software (LaserGene).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07953-w ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:708 | https://doi.org/10.1038/s41467-018-07953-w |www.nature.com/naturecommunications 11
mRNA extraction and RT-qPCR for zebrafish studies. Total RNA from 1, 3, and
5 dpf vars+/+, vars+/−, and vars−/− larvae, respectively, was extracted using
TRIzol (Ambion, Life Technologies). Residual genomic DNA was removed by
treatment with DNase I (Roche) with Protector RNase inhibitor (Roche). Reverse
transcription of total RNA to single-stranded cDNA was performed on 1 μg of
total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems) and further diluted 1:20. Real-time PCR was performed in HardShell®
Low-Profile Thin-Wall 96-Well Skirted PCR Plates (Bio-Rad) using CFX96 Touch
Real-Time PCR Detection System (Bio-Rad). Primer and probe sequences for real-
time detection of endogenous vars, as well as injected human WT VARS were
custom-made (Supplementary Table 3). Reaction mixture containing diluted
cDNA template, primers and 2x SsoAdvanced Universal SYBR Green Supermix
(Bio-Rad) was amplified under cycling conditions according to the manufacturer’s
protocol. Data generated were analysed using CFX Manager Software (Bio-Rad).
vars transcripts were normalized against ribosomal protein S18 (rps18) house-
keeping genes that were experimentally determined to have the most stable
expression in our reaction conditions. Primer and probe sequences for real-time
detection of vars in Hi558Tg line were purchased from IDT (Supplementary
Table 3). 2x TaqMan Universal Master Mix (ABI, USA) was used for the reaction.
vars transcripts normalization was done against elongation factor 1-alpha (ef-1
alpha) and rps18. The ΔΔCq method was used to determine the relative levels of
mRNA expression between experimental samples and controls. The results consist
of data from at least two separate experiments run in triplicate. One-way ANOVA
with Tukey’s multiple comparisons test was used to determine statistical
significance.
Morphological studies in vars−/− zebrafish larvae. Surviving vars+/+,
vars+/−, and vars−/− larvae were counted daily and examined for major
dysmorphologies, such as edema, head, and eye malformations, and for the
presence of touch response, from 1 until 12 dpf. Dead larvae and all larvae from
12 dpf onwards were collected, stored at −80 °C and genotyped.
For head size measurements, vars+/+, vars+/−, and vars−/− larvae were
positioned in 3% methylcellulose. Lateral images of the head and the whole body
of 3 and 5 dpf larvae were acquired using Leica MZ 10F fluorescence microscope
with a Leica DFC310 FX digital camera and Leica Application Suite V3.6 software.
Measurements were done blinded, manually in ImageJ software. Body length was
measured from the anterior tip of the snout to the base of the posterior caudal fin.
Head, brain, and eye areas were measured by tracing the boundary of the surface
of interest using some predetermined spots on the head such as the otic vesicle
or dorsal indentation just above the eye, at the level of the pineal gland. The
absolute values of measured surface were normalized to the total body length of
the larvae. Results were analysed using one-way ANOVA followed by Tukey’s
multiple comparisons test.
Histological analysis of vars−/− zebrafish larvae. Fin clipped larvae were fixed
in 4% PFA at 4 °C overnight and kept in 70% ethanol. At least five embryos or
larvae per genotype group were embedded in 1% agarose in 1X TAE buffer. A
mould, specifically designed to align zebrafish larvae, was used to produce agarose
blocks with identical distributed wells of the same depth. Agarose blocks were
gradually dehydrated in an enclosed automated tissue processor (Shandon Excel-
sior ES, Thermo Scientific) and subsequently embedded in paraffin. The heads of
paraffin-embedded larvae were sectioned on a HM 325 manual rotary microtome
(Thermo Fisher Scientific) at a thickness of 5 μm. The specimens were stained with
hematoxylin and eosin (H&E stain) using Varistain™ Gemini ES Automated
Slide Stainer (Thermo Fisher Scientific) according to laboratory protocols. The
resulting sections were imaged at ×20 magnification in a SPOT 5.1 software
(SPOT Imaging) by a SPOT-RT3 camera mounted on a Leica microscope.
Brightness of the images was adjusted for the white background.
Immunohistochemistry for active caspase-3. IHC detection of cell death was
carried out on 5-μm-thick deparaffinised and rehydratated sections. Prior to IHC,
the specimens were subjected to heat-induced antigen retrieval by incubation in 10
mM sodium citrate (pH 6.0) for 10 min at 98 °C, followed by a 30 min cool down
and treatment with 3% hydrogen peroxide (2 × 8 min). The sections were blocked
for 30 min in 5% normal goat serum in 1X TBST, and further incubated with
primary antibody against active caspase-3 (BD Biosciences, Clone C92-605, 1:500
dilution) for 1 h at RT. After rinsing with 1X TBST, HRP-conjugated secondary
antibody (Jackson ImmunoResearch, 111-035-003, 1:200 dilution) was applied for
1 h at RT. Next, the slides were treated with DAB+/chromogen (DAKO) for 1 min
at RT and rinsed with deionized water. Nuclear counterstain was performed in
hematoxylin for 3 min. After clearing in ethanol and histoclear, the slides were
coverslipped under mounting medium. For each staining a negative control was
included by processing sections in the absence of the primary antibody. The images
were taken at ×40 magnification in a SPOT 5.1 software (SPOT Imaging) by a
SPOT-RT3 camera mounted on a Leica microscope. Three to four equivalent
sections were selected for each group and DAB positively stained nuclei were
counted using Fiji. The results were expressed as percentage of apoptotic cells of the
total cell number within a selected brain area. Results were analysed using one-way
ANOVA followed by Tukey’s multiple comparisons test.
Behavioral studies in vars−/− zebrafish larvae. For the locomotor tracking, 3–7
dpf vars+/+, vars+/−, and vars−/− larvae were individually arrayed in a 96-well
plate. After 30 min habituation, the larvae were placed in an automated tracking
device (ZebraBoxTM, Viewpoint, Lyon, France) and their locomotor behavior was
followed for 1 h under dark conditions. The total movement was quantified
using ZebraLab software (Viewpoint, Lyon, France) and expressed in actinteg units.
The results were analysed by one-way ANOVA with Tukey’s multiple comparisons
test.
For the habituation assay, 6 dpf vars+/+, vars+/−, and vars−/− larvae were
individually arrayed in a 96-well plate and equilibrated for 3 h in a uniformly
illuminated testing chamber in an automated video-tracking device (ZebraBoxTM,
Viewpoint, Lyon, France). Further, they were exposed to a spaced training with
light/dark cycles consisting of four blocks of 120 dark flashes (DFs) with 15 s
interstimulus intervals (ISI) alternated with 10 min light periods. The increased
movement during DFs was expressed in actinteg units. For the sake of clarity,
standard deviations were not shown in the graph. Linear regression was used to
find the best-fitting straight line through all the data points for each genotype
group.
Non-invasive local field potential recordings in vars−/− zebrafish larvae. A
larva was embedded in 2% low melting point agarose (Invitrogen). Recording
electrodes were pulled from soda lime glass capillaries (1412227, Hilgenberg,
Germany) on a DMZ Universal Puller (Zeitz, Germany) to a diameter of ~20
microns. It was filled with artificial cerebrospinal fluid (ACSF, 124 mM, NaCl,
2 mM KCl, 2 mM MgSO4, 2 mM CaCl2, 1.25 mM KH2PO4, 26 mM NaHCO3, and
10 mM glucose) and placed on larva’s head above the optic tectum. The recordings
were performed using WinEDR (John Dempster, University of Strathclyde, UK).
Differential signal was amplified 10,000 times by DAGAN 2400 amplifier
(Minnesota, USA), band pass filtered at 0.3–300 Hz and digitized at 2 kHz via a
PCI-6251 interface (National Instruments, UK).
All the larvae used for LFPs displayed touch response. The duration of each
recording was 10 min. An electrical discharge was classified as a positive event
when its amplitude was at least three times the amplitude of the baseline, and had
a duration of at least 100 ms. The analysis of the epileptiform events was done
using automated detection software that was previously developed and validated
by our group46.
VARS rescue experiments. Full-length wild-type human VARS cDNA (GenBank
BC012808.2 from IRAUp969E0949D clone purchased from Source BioScience,
UK) was cloned into a pCSDest vector (Addgene) using Gateway recombination
technology according to the manufacturer’s instructions (Life Technologies) (WT
VARS-pCSDest). Single nucleotide variants, leading to substitutions p.Gln400Pro,
p.Arg942Gln, and p.Arg1058Gln at protein level, were introduced into WT
VARS-pCSDest vector via site-directed mutagenesis using PWO SuperYield DNA
polymerase (Roche) and primers containing given variants (Supplementary
Table 3). Subsequent DpnI digestion was done to remove parental plasmid. All
templates were verified by direct Sanger sequencing.
Wild-type, p.Gln400Pro, p.Arg942Gln, and p.Arg1058Gln VARS mRNA was
transcribed from linearized template plasmids using the SP6 mMessage
mMachine® kit (Ambion) and purified by lithium chloride precipitation (Ambion).
The rescue experiment was performed by cytoplasmic microinjection of 200 pg of
WT or mutant VARS and GFP mRNA as control (1 nL volume) into 1-cell-stage
vars−/− embryos. Following the injections, at 24 hpf only the healthy-looking
embryos with normal morphology were selected for subsequent experiments
(survival, behavioral tracking, and head measurements).
Statistical analysis. Data are presented as mean ± SD or mean ± SEM. Pairwise
statistical significance was calculated with Student’s unpaired t-test or
Mann–Whitney test for data that failed the normality test and multiple compar-
isons were determined with one-way ANOVA with Tukey’s test, using GraphPad
Prism7 software.
Data availability
All data generated or analysed during this study are included in this published
article (and its supplementary information files). Human sequence (variant) data
that support the findings of this study have been deposited in ClinVar and are
accessible through the accession codes: ID:402133, ID:402134, SCV000808053,
SCV000808054, SCV000808055, SCV000808056, SCV000808057, SCV000808058
and SCV000808059. All other relevant data are available from the corresponding
authors on request.
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